Retinal Degeneration
Retinal degeneration refers to a group of progressive disorders characterized by the deterioration of the retina, the light-sensitive tissue lining the inner surface of the eye. The retina is essential for capturing visual information and transmitting it to the brain via the optic nerve. Pathogenetically, retinal degeneration involves the progressive loss of photoreceptor cells (rods and cones) and/or the supporting retinal pigment epithelium (RPE), often through mechanisms such as genetic mutations, oxidative stress, inflammation, or metabolic dysfunction. This cellular loss disrupts the retinal architecture and impairs its function, ultimately leading to visual impairment or blindness. The health impacts of retinal degeneration are profound, affecting quality of life, independence, and the ability to perform daily activities. Inherited forms often present in childhood or young adulthood, while acquired forms, such as age-related macular degeneration, typically manifest later in life.
Retinitis pigmentosa (RP) is a group of inherited retinal dystrophies characterized by progressive peripheral vision loss and night blindness, followed by central vision deterioration. RP results from genetic mutations affecting photoreceptor function and survival, leading to the accumulation of pigment deposits in the retina and gradual photoreceptor cell death. The disease course varies, but most individuals eventually experience significant visual impairment.
Age-related macular degeneration (AMD) is a leading cause of vision loss among the elderly, involving the degeneration of the macula, the central area of the retina responsible for sharp, detailed vision. AMD is classified into 'dry' (atrophic) and 'wet' (neovascular or exudative) forms. The dry form involves gradual thinning of the macula and drusen deposition, while the wet form is characterized by abnormal blood vessel growth and leakage, leading to rapid central vision loss.
Stargardt disease is the most common inherited juvenile macular degeneration, resulting from mutations in the ABCA4 gene. It typically presents in childhood or adolescence with progressive central vision loss, while peripheral vision is usually preserved. Characteristic features include yellowish flecks in the retina and macular atrophy.
Cone-rod dystrophy is a group of hereditary retinal degenerations in which cone photoreceptors are primarily affected, leading to early loss of central vision, color discrimination, and visual acuity, followed by rod dysfunction resulting in peripheral vision loss and night blindness. The onset and severity can vary depending on the underlying genetic defect.
Choroideremia is an X-linked recessive retinal degeneration caused by mutations in the CHM gene, leading to progressive loss of the choroid, RPE, and photoreceptors. It predominantly affects males and is characterized by night blindness in childhood, followed by progressive peripheral vision loss and eventual central vision impairment.
Retinal degenerative diseases collectively represent a significant cause of irreversible vision loss worldwide. Retinitis pigmentosa has an estimated prevalence of 1 in 3,000 to 1 in 5,000 individuals globally, affecting both males and females, with variations depending on geographic and ethnic factors. Age-related macular degeneration is the leading cause of blindness among individuals over 60 years of age in developed countries, with a prevalence of approximately 8.7% in the global population aged 45–85 years; the risk increases with advancing age. Stargardt disease is less common, with an estimated prevalence of 1 in 8,000 to 1 in 10,000. Cone-rod dystrophies and choroideremia are rare, with choroideremia affecting approximately 1 in 50,000 to 1 in 100,000 males. The burden of retinal degeneration is expected to rise with increasing life expectancy and the aging global population.
Diagnosis of retinal degeneration involves a comprehensive clinical evaluation, including detailed patient history, assessment of visual symptoms (such as night blindness, peripheral or central vision loss), and family history of ocular disease. Ophthalmic examination includes visual acuity testing, color vision assessment, and funduscopy to detect characteristic retinal changes such as pigmentary alterations, drusen, or atrophy. Advanced imaging modalities are critical for diagnosis and disease monitoring: optical coherence tomography (OCT) enables high-resolution cross-sectional imaging of retinal layers, revealing thinning, atrophy, or subretinal deposits; fundus autofluorescence highlights metabolic changes in the retinal pigment epithelium; and fluorescein angiography is used to detect neovascularization in conditions like wet AMD. Electrophysiological tests, such as electroretinography (ERG), assess retinal function by measuring electrical responses of photoreceptors and inner retinal cells. Genetic testing is increasingly employed to identify causative mutations, confirm diagnosis, and inform prognosis and eligibility for emerging gene-based therapies. Diagnostic criteria typically include characteristic clinical findings, supportive imaging and functional test results, and, when available, molecular genetic confirmation.
Make Order
Experimental Scheme
Implementation
Conclusion
